practice patterns. CONCLUSIONS: The interviews allowed to extrapolate European findings to the Asia-Pacific region and therefore improved the validity of the costeffectiveness models developed for these countries. In our opinion, this methodology represents an acceptable alternative when more time-consuming and costly chart reviews cannot be repeated in multiple countries. The significant economic burden of OAG was confirmed.
PSS6 HEALTH ECONOMIC EVALUATION OF PRESERVATIVE-FREE TAFLUPROST VERSUS PRESERVED LATANOPROST IN THE TREATMENT OF OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION (OH)
Makino K 1 , Charles H 2 , Tilden D 1 , Cottrell S 1 , Mudge M 1 , Christova L 1 , Van Bavel J 2 , West B 2 , Woodgate AM 2 1 THEMA Consulting Pty. Ltd., Pyrmont, NSW, Australia, 2 Merck Sharp & Dohme (Australia) Pty.
Limited, North Ryde, NSW, Australia OBJECTIVES: Safety and efficacy of tafluprost for open-angle glaucoma or ocular hypertension (OH) have been proven in clinical trials. While tafluprost and latano-prost have similar efficacy, the absence of the preservative benzalkonium chloride (BAK) in tafluprost may make it a preferred alternative for patients who are intolerant to BAK (i.e., reduces adverse ocular symptoms such as irritation and dry eye). Reduced ocular symptoms offer clinical/QoL benefits and cost savings associated with less rescue medication use (artificial tears). Further, the single-dose unit formulation of tafluprost is predicted to lessen medication wastage and thus generate cost savings versus latanoprost (dispensed in multi-dose bottles). These cost-savings are quantified and cost-effectiveness ratios are calculated in the current study. METHODS: Resource usage and associated costs are quantified to determine cost savings offered by tafluprost over latanoprost. Disutility from adverse ocular symptoms caused by preservatives is also determined via a systematic review of literature to transform tafluprost's superior tolerability to QALYs. The perspective of this analysis is the Australian health care system. RESULTS: Preservative-free tafluprost was shown to be a highly cost-effective, most likely dominant, strategy over preserved latanoprost. The likely cost savings due to reduced medication wastage, informed by the pattern of latanoprost utilisation observed in the Australian drug reimbursement system (PBS), in itself would make tafluprost a cost-saving strategy versus latanoprost. The available evidence suggested that 47.6% of patients on preserved latanoprost experience some adverse ocular symptoms, while this is expected to be 29.0% with preservative-free tafluprost. Average cost savings attributable to reduced artificial tear use was estimated to be $23.64 per patient per year. This superior tolerability is also estimated to produce an incremental QALY of 0.0107 for preservative-free tafluprost each year when compared with preserved latanoprost. CONCLUSIONS: Preservative-free tafluprost is a highly cost-effective, most likely dominant, strategy over preserved latanoprost. 
PSS7 COST EFFECTIVENESS ANALYSIS OF COMMUNITY SCREENING FOR GLAUCOMA IN INDIA

OBJECTIVES:
To investigate the cost-effectiveness of a hypothetical community screening and subsequent treatment programme for glaucoma in comparison with current practice (i.e. with no screening programme but with some opportunistic case finding), in both urban and rural areas of India. METHODS: A decision analytical model was built to model events, costs and treatment pathways with and without a hypothetical screening programme for glaucoma for a population aged between 40-69 years age in urban and rural areas. The treatment pathway included both primary open-angle glaucoma and angle closure disease. Screening and treatment costs were obtained from an administrator of a tertiary eye hospital in India. The probabilities for each pathway (i.e. for urban and rural areas) were derived from published literature and expert opinion (Glaucoma specialist currently practicing in India). The glaucoma prevalence rates for urban and rural areas were adapted from the Chennai Glaucoma Study findings. Separate decision analytical models for urban and rural areas were built for calculating the cost-effectiveness of community screening for glaucoma in comparison to current practice (i.e. no screening programme with some opportunistic case finding). The outcomes calculated were the incremental cost of screening (i.e. compared with no screening), the additional cases treated with screening; and the cost per QALY gained by screening. RESULTS: The introduction of a community screening programme for glaucoma is likely to be cost-effective, the estimated ICER values being x 8312.71 for urban areas and x 7292.30 for rural areas, when compared with no screening programme. The community screening for glaucoma would treat an additional 4443 cases and 2872 cases, and prevent 1790 person-years of blindness, and 1150 person-years of blindness over a 10-year period, in urban and rural areas respectively. CONCLUSIONS: If adequate resources (trained medical personnel and equipment) is available the likelihood of community screening for glaucoma to be cost-effective and have an impact on reducing glaucoma-related blindness burden, remains high in India.
SENSORY SYSTEMS DISORDERS -Patient-Reported Outcomes & Patient Preference Studies
PSS8 HEALTH BURDEN OF VISION PROBLEMS IN ASIA: A STUDY OF MALAYS AND INDIANS IN SINGAPORE
Ϫ0.02, pϭ0.042), low vision in both eyes (difference: Ϫ0.02, pϭ0.041), and blindness in both eyes (difference: Ϫ0.10, pϽ0.0001) had lower EQ-5D score than those without visual impairment. Singapore Indians with low vision in both eyes (difference: Ϫ0.03, pϭ0.0081), low vision in one eye and blindness in the other eye (difference: Ϫ0.09, pϽ0.0001), and blindness in both eyes (difference: Ϫ0.16, pϭ0.0004) had lower EQ-5D score than those without visual impairment. After adjusted for age, gender and co-morbidities, none of the 5 eye conditions was associated with reduction in EQ-5D scores in Malays or Indians, except that Indians with cataract had lower EQ-5D scores than those without cataract (difference: Ϫ0.02, pϭ0.0431). CONCLUSIONS: Health burden is associated with visual impairment, but not with the presence of the eye conditions. Vision problems pose more health burden to Indians than Malays in Singapore. 
URINARY/KIDNEY DISORDERS -Clinical Outcomes Studies
PUK1 DIURETIC ACTIVITY OF AQUEOUS EXTRACT OF BOSWELLIA SERRATA ROXB. OLEO GUM IN NORMAL ALBINO RATS
OBJECTIVES:
To evaluate the effect of aqueous extract of Boswellia serrata Roxb oleo gum on urinary electrolytes, pH and diuresis in normal albino rats. METHODS: Oleo gum weighing 500g was soaked in hot boiling water (1L) at room temperature for 3 days with occasional shaking. Filtrate was evaporated on rotary evaporator under reduced pressure (Ϫ760 mmHg) to a thick, semi-solid pasty mass of dark drown color that was completely solubilized in both distilled water and normal saline for in-vitro and in-vivo experimentation. Phytochemical analysis was carried out for alkaloids, saponins, anthraquinones, flavanoids and tannins. For invivo activity, five groups of with six animals in each were administered normal saline (10 ml/Kg, i.p.), Furosemide (10mg/kg) and crude extracts of Boswellia sarrata (10, 30 and 50mg/kg of body weight), respectively. Toxicological effect of plant was undertaken in rats at a dose of 3000mg/kg. Data was expressed as mean Ϯ SEM and analyzed using Graph Pad Prism (Graph PAD, San Diego, USA). Student t-test was applied for data analysis. p values Ͻ0.05 were considered significant. RESULTS: Phytochemical screening of Boswellia serrata Roxb confirmed the presence of saponins and flavonoids. Furosemide induced significant diuresis and electrolytes (Na ϩ & K ϩ ) excretion while plant extracts increased urinary output and electrolytes excretion in a dose-dependent manner. Diuretic index of test groups were1.36, 2.06 and 2.9, respectively while, Lipschitz value also confirmed diuretic activity in dose dependent manner. Urinary pH remained unchanged during the course of the study whereas, no lethality was observed at the dose of 3000mg/kg. CONCLUSIONS: Aqueous Boswellia serrata oleo gum extracts administered particularly at the dose of 50mg/kg significantly induced water and electrolytes with no signs of toxicity.
URINARY/KIDNEY DISORDERS -Cost Studies
PUK2 ECONOMIC BURDEN OF HEMODIALYSIS AND PERITONEAL DIALYSIS IN A TERTIARY HOSPITAL IN CHINA
Zhang X 1 , Xuan X 2 , Wan Y 3 , Ye L 4 , Gao X 3 1 Shenzhen People 's Hospital, Shenzhen, Guangdong, China, 2 No. 2 Hospital of Xiamen, Xiamen, Fujian, China, 3 Pharmerit, Bethesda, MD, USA, 4 School of Public Health, Fudan University, Shanghai, Shanghai, China OBJECTIVES: To assess economic burden associated with hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) among patients with end-stage renal disease (ESRD) and treated in a tertiary hospital in China. METHODS: From Sept 2004 to Jan 2005, adult patients on HD or CAPD for at least 6 months were recruited. Resource utilization and costs were collected by medical records review and patient survey. The economic burden was divided into direct costs including medical (dialysis, drugs, lab, and inpatient) and nonmedical (transportation, hired caregivers, and special nutritional products) and indirect costs due to productivity loss (human capital approach). The annualized costs expressed in 2010 Yuan(¥) were analyzed using Wilcoxon test and General Linear Model with gamma distribution and log link. RESULTS: Eighty-six patients [50 on CAPD and 36 on standard HD (3x4-hour weekly)] were included for the analysis, with 55% male and a mean age of 57.7Ϯ15.6 years. No differences were found in age, sex, education, payment method, income, originating disease, haemoglobin level, and dialysis time between HD and CAPD. Mean(SD)/Median of annual medical expenses were ¥91,476(42,935)/¥82,478 for HD and ¥68,898(11,698)/¥68,191 for CAPD (pϽ0.0001); nonmedical direct expenses were ¥5,883(4,256)/¥4,780 for HD and ¥3,041(3,835)/ ¥1,300 for CAPD (pϽ0.0001). No difference was found in indirect costs [¥3,167 (6,992) for HD and ¥5,064 (8,354) for CAPD (pϭ0.3)]. Total annual costs were ¥100,403(44,419)/¥90,262 for HD and ¥79,859(22,210)/¥77,681 for CAPD (pϭ0.001). Controlling for key factors/covariates, HD patients incurred 16% higher total cost compared to CAPD patients (pϭ0.01). Patients with younger age (pϭ0.005), public health insurance (pϽ0.0001), or originating disease of diabetes (pϭ0.03) incurred higher total costs compared to their counterparts, respectively. CONCLUSIONS: Patients received HD incurred more direct costs compared to patients undergoing CAPD. The findings of this study may help understand the disease burden and establish cost-effective treatment modalities in ESRD from Chinese societal perspective.
PUK3 EVALUATION ON HEALTH EXPENDITURE AMONG PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY AFTER SPINAL CORD INJURY
Lai ECC 1 , Kao Yang YH 1 , Kuo HC 2 , Ng K 3 , Cheng E 4 1 Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Tainan City, Taiwan, 2 Department of Urology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan, 3 Allergan Singapore Pte. Ltd., Singapore, Singapore, 4 Market Access, Allergan Pharmaceuticals, Taipei, Taiwan
